Black Diamond Therapeutics Inc Cash Flow Quality Index

Latest as of March 2025: 0.94x

Black Diamond Therapeutics Inc cash flow quality index. Black Diamond Therapeutics Inc (BDTX) has a Cash Flow Quality Index of 0.94x as of March 2025. Operating cash flow of $53.41 Million is below net income of $56.54 Million, suggesting accrual-heavy earnings not yet converted to cash. See financial agility of Black Diamond Therapeutics Inc to measure the company's free cash flow as a share of total liabilities.

Cash Flow Quality Index

0.94x

Operating CF / Net Income

Operating Cash Flow

$53.41 Million

USD

Net Income

$56.54 Million

USD

Data as of

Mar 2025

Most recent filing

Cash Flow Quality Index of Black Diamond Therapeutics Inc (2025–2025)

Cash flow quality index of Black Diamond Therapeutics Inc from 2025 to 2025. Historical Cash Flow Quality Index for Black Diamond Therapeutics Inc across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore Black Diamond Therapeutics Inc cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.

Black Diamond Therapeutics Inc Cash Flow Quality Index by Year (2025–2025)

Black Diamond Therapeutics Inc cash flow quality index by year from 2025 to 2025. Year-by-year earnings quality comparison for Black Diamond Therapeutics Inc. For the full cash flow conversion analysis, see cash efficiency ratio of Black Diamond Therapeutics Inc.

Year	Quality Index	Operating CF (USD)	Net Income	YoY Change
2025	1.32x	$29.61 Million	$22.37 Million	—

Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.